Listeria Monocytogenes

The standard adult dosage for Listeria Monocytogenes allergenic extract is 0.1 mL of the specified concentration (usually a 1:100 or 1:1000 w/v dilution, depending on the manufacturer's instructions and the patient's suspected sensitivity). The injection must be administered intradermally, typically on the volar surface (inner side) of the forearm.

Clinicians often use a 26- or 27-gauge needle and a tuberculin syringe. The goal is to produce a small, distinct bleb (a raised bubble of fluid) approximately 6-10 mm in diameter. If the bleb does not form, the injection may have been too deep (subcutaneous), which can lead to inaccurate results and increased risk of local irritation.

Listeria Monocytogenes extract is generally considered safe for use in children when used for diagnostic purposes, although its use is less common than other antigens like Candida or Mumps. The dosage is typically the same as the adult dose (0.1 mL intradermally). However, the reactivity of the immune system in infants under 6 months of age may be immature, leading to a higher rate of false-negative results. Healthcare providers must exercise caution when interpreting results in the very young.

Renal Impairment

No dosage adjustments are required for patients with kidney disease, as the extract is not cleared through the kidneys in a manner that would affect its diagnostic utility or safety.

Hepatic Impairment

No dosage adjustments are required for patients with liver disease. The metabolic breakdown of the extract occurs locally at the injection site and via the lymphatic system, not through hepatic pathways.

Elderly Patients

While the dose remains 0.1 mL, elderly patients often exhibit "immunosenescence" (a natural decline in immune function). This may result in smaller induration sizes even in the absence of a specific disease state. Healthcare providers should consider this when evaluating the results.

This product is never self-administered. It must be administered by a trained healthcare professional in a clinical setting equipped to handle potential allergic reactions.

• Site Selection: The skin should be clean and free of rashes, scars, or tattoos that could interfere with reading the result. The forearm is the preferred site.
• Storage: The extract must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It should never be frozen. Exposure to light should be minimized.
• Reading the Test: The patient must return to the clinic 48 to 72 hours after the injection. The healthcare provider will measure the diameter of the induration (the hard bump), not the erythema (the redness). A positive test is generally defined as an induration of 5 mm or greater, though this threshold can vary based on the clinical context.

Since this is a one-time diagnostic test, a "missed dose" refers to a missed appointment for reading the test. If the patient does not return within the 48-72 hour window, the test is considered invalid and must be repeated on the opposite arm after the initial site has completely healed.

An overdose of an allergenic extract is rare but can occur if an incorrect concentration is used or if the injection is given more frequently than recommended. Signs of a local overdose include severe swelling, pain, and potential skin necrosis (tissue death) at the injection site. Systemic reactions (anaphylaxis) are the primary concern with accidental high-dose administration. In the event of an overdose, the site should be monitored, and emergency protocols for anaphylaxis (including epinephrine administration) should be initiated if systemic symptoms appear.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to read your own skin test results without medical guidance.

Most patients receiving the Listeria Monocytogenes skin test will experience some level of local reaction, which is often a sign that the test is working.

• Local Erythema (Redness): A red area around the injection site is very common and usually appears within a few hours. It typically fades within 2-3 days.
• Induration (Hardness): This is the expected diagnostic response. It may feel like a small, firm pea under the skin. It can be slightly tender to the touch.
• Pruritus (Itching): Many patients report mild to moderate itching at the injection site. This is due to the release of histamines and other inflammatory mediators during the immune response.
• Tenderness: The site may feel sore, similar to a small bruise, for 24 to 48 hours.

• Persistent Discoloration: Some patients may notice a small brown or red spot at the injection site that lasts for several weeks after the test has concluded.
• Local Edema: Significant swelling of the area surrounding the injection site, which may extend beyond the initial bleb area.
• Vesiculation: In highly sensitive individuals, small blisters (vesicles) may form on the surface of the induration.

• Skin Necrosis: In extremely rare cases of hypersensitivity, the skin at the center of the test site may break down, leading to a small ulcer or scar.
• Lymphangitis: Inflammation of the lymph vessels leading away from the injection site, appearing as a red streak on the arm.
• Fever and Malaise: A very small percentage of patients may experience a low-grade fever or a general feeling of being unwell as their immune system responds to the antigen.

While extremely rare for diagnostic skin tests, systemic allergic reactions can occur.

> Warning: Stop taking Listeria Monocytogenes and call your doctor immediately if you experience any of these symptoms after the injection:

• Anaphylaxis: A life-threatening allergic reaction characterized by a sudden drop in blood pressure, difficulty breathing, and loss of consciousness.
• Angioedema: Severe swelling of the face, lips, tongue, or throat, which can obstruct the airway.
• Generalized Urticaria: Hives that spread across the entire body, far away from the injection site.
• Wheezing or Chest Tightness: Signs of bronchial constriction.
• Tachycardia: A rapid or irregular heartbeat accompanied by dizziness.

There are no known long-term systemic side effects associated with the one-time diagnostic use of Listeria Monocytogenes extract. The extract does not remain in the body for an extended period, and it does not cause permanent changes to the immune system. The only potential long-term effect is a small, localized scar at the injection site if a severe local reaction or ulceration occurred.

No FDA black box warnings are currently issued for Listeria Monocytogenes allergenic extract. However, like all allergenic extracts, it carries a general warning regarding the risk of severe systemic reactions and the requirement for administration by qualified personnel in a setting where emergency resuscitation is possible.

Report any unusual symptoms, especially those occurring within the first 30 minutes after injection, to your healthcare provider immediately.

Listeria Monocytogenes extract is a diagnostic tool, not a treatment. It should only be administered by healthcare professionals who are experienced in intradermal testing and the management of potential allergic reactions. Patients should remain in the medical office for at least 30 minutes following the injection to monitor for immediate hypersensitivity reactions.

No FDA black box warnings for Listeria Monocytogenes. While some standardized allergenic extracts used for immunotherapy carry black box warnings for anaphylaxis, this non-standardized diagnostic extract does not currently have this designation. However, the risk of anaphylaxis is inherent to all allergen exposures.

• Allergic Reactions / Anaphylaxis Risk: Although the amount of antigen in a 0.1 mL dose is very small, individuals with extreme sensitivity to bacterial proteins or the preservatives used in the extract (such as phenol) may experience systemic reactions. Healthcare providers must have epinephrine (1:1000) and other emergency supplies readily available.
• Infection at the Site: The injection should never be performed through infected, inflamed, or damaged skin. This can lead to the introduction of bacteria into the deeper layers of the skin or interfere with the reading of the test.
• Immunosuppression Interference: Patients taking high doses of systemic corticosteroids or other immunosuppressive drugs may have a suppressed DTH response, leading to a false-negative result. This does not mean the test is unsafe, but rather that the results may not accurately reflect the patient's underlying immune status.
• Bleeding Disorders: Patients with severe thrombocytopenia (low platelet count) or those on high-dose anticoagulant therapy may experience significant bruising or hematoma formation at the injection site.

No specific laboratory tests (like blood counts or liver panels) are required before or after the administration of Listeria Monocytogenes extract. The primary monitoring requirement is the clinical observation of the injection site and the patient's systemic status for 30 minutes post-injection, followed by a formal reading of the skin site 48 to 72 hours later.

Listeria Monocytogenes extract does not cause drowsiness or cognitive impairment. Patients are generally safe to drive or operate machinery immediately after the 30-minute observation period, provided they have not experienced a systemic reaction.

There is no direct pharmacological interaction between alcohol and Listeria Monocytogenes extract. However, excessive alcohol consumption can cause peripheral vasodilation (widening of blood vessels), which might theoretically increase the redness at the injection site, making the test harder to read accurately. It is advisable to avoid heavy alcohol use for 72 hours following the test.

As this is a single-dose diagnostic test, there is no "discontinuation" or tapering process. Once the test is read at 72 hours, no further action is required.

> Important: Discuss all your medical conditions, especially any history of severe allergies or immune system disorders, with your healthcare provider before starting Listeria Monocytogenes testing.

There are no absolute drug-drug contraindications where the combination is lethal. However, the use of Live Viral Vaccines (such as MMR or Varicella) should be carefully timed. Administering a DTH skin test at the same time as a live vaccine may theoretically interfere with the immune response to either the vaccine or the skin test. It is generally recommended to wait 4-6 weeks after live vaccination before performing DTH testing.

• Systemic Corticosteroids (e.g., Prednisone): High doses of steroids (typically >20 mg/day of prednisone for more than two weeks) can significantly blunt the T-cell response. This leads to a high risk of false-negative results. If possible, testing should be delayed until the steroid dose is reduced, or the results should be interpreted with extreme caution.
• Biologic Response Modifiers (e.g., TNF-alpha inhibitors like Adalimumab, Etanercept): These drugs specifically block the cytokines required to produce the induration in a DTH test. Patients on these medications will likely show no reaction to the Listeria extract regardless of their true immune status.
• Chemotherapy Agents: Cytotoxic drugs that deplete white blood cells will naturally reduce the body's ability to mount a DTH response.

• H1-Antihistamines (e.g., Cetirizine, Loratadine): While DTH is a delayed T-cell reaction, the initial "wheal and flare" (immediate reaction) can be suppressed by antihistamines. This usually does not affect the 48-hour induration reading, but it may mask an immediate allergic sensitivity to the extract components.
• H2-Antihistamines (e.g., Famotidine): Similar to H1 blockers, these may slightly alter the local inflammatory environment but are unlikely to invalidate the 72-hour reading.

There are no known food interactions with Listeria Monocytogenes extract. Unlike the Listeria bacteria, the extract is not absorbed through the digestive tract, so dietary choices do not affect its diagnostic performance.

• Echinacea and Astragalus: These herbs are often taken to "boost" the immune system. While there is limited clinical data, they could theoretically enhance the inflammatory response at the skin test site, potentially leading to a larger induration.
• High-dose Vitamin C: Some studies suggest very high doses of antioxidants might subtly modulate cytokine release, though this is unlikely to be clinically significant for a DTH test.

Listeria Monocytogenes extract can interfere with other skin tests. For example, if multiple skin tests are placed too close together on the arm, the inflammation from a strong reaction to one (e.g., a positive Tuberculin test) can spill over and cause a false-positive reading for the Listeria test. Tests should be spaced at least 2-5 cm apart.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your immune system.

Listeria Monocytogenes extract must NEVER be used in the following circumstances:

• Known Severe Hypersensitivity: If a patient has a documented history of anaphylaxis or severe systemic reactions to previous Listeria extract testing or any of the inactive ingredients (such as phenol or sodium chloride), the test is strictly contraindicated. The risk of a life-threatening reaction outweighs any diagnostic benefit.
• Previous Severe Local Reaction: If a prior skin test resulted in significant skin necrosis, ulceration, or scarring at the injection site, the test should not be repeated, as subsequent exposures can lead to even more exaggerated local tissue destruction.

In these cases, the healthcare provider will perform a risk-benefit analysis:

• Acute Viral or Bacterial Infection: During an active infection, the immune system is "preoccupied," which can lead to transiently suppressed DTH reactivity. It is usually best to wait until 2-4 weeks after the patient has recovered.
• Recent Live Vaccine Administration: As mentioned, recent vaccination can cause temporary changes in T-cell trafficking and cytokine profiles, potentially skewing the results.
• Uncontrolled Skin Disease: Conditions like generalized eczema or psoriasis can make it impossible to find a clear area of skin for testing and can lead to "Isomorphic" responses (the Koebner phenomenon), where the skin disease develops at the site of the injection.

There is a potential for cross-sensitivity between different bacterial extracts. Patients who are highly sensitive to other Gram-positive bacterial antigens may exhibit a more robust reaction to Listeria Monocytogenes. However, there is no known cross-reactivity that would pose a unique safety hazard beyond standard allergic precautions.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of "anergy" or severe allergic reactions, before prescribing Listeria Monocytogenes testing.

Listeria Monocytogenes extract is categorized as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm or affect reproduction capacity.

Because the extract is used for diagnostic purposes and involves only a minimal, localized dose of bacterial proteins, it is generally considered low-risk. However, it should be administered to a pregnant woman only if clearly needed. The main concern is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother, which could lead to fetal hypoxia (lack of oxygen). Testing is often deferred until after delivery unless the assessment of the mother's immune system is critical for managing a serious underlying condition.

It is not known whether the components of Listeria Monocytogenes extract are excreted in human milk. However, given the tiny dose (0.1 mL) and the fact that the proteins are primarily degraded locally or in the lymphatics, it is highly unlikely that any significant amount would reach the breast milk. There are no known risks to the nursing infant. Breastfeeding is generally not considered a reason to avoid DTH skin testing.

Listeria Monocytogenes extract is safe for use in the pediatric population for the diagnostic evaluation of cellular immunity. As noted previously, infants under 6 months of age may have lower reactivity due to an immature immune system. In children, the forearm remains the preferred site, but in very small children, the upper back may be used if the forearm does not provide enough surface area. Healthcare providers should be mindful that a child's distress during the injection can cause local flushing, which should not be confused with an immediate allergic reaction.

In patients over the age of 65, the prevalence of anergy (no reaction to skin tests) increases. This is often due to the natural aging of the immune system rather than a specific disease. When testing elderly patients, clinicians should be aware that a negative result may not be as clinically significant as it is in a younger adult. There are no specific safety concerns unique to the elderly, provided they do not have severe skin fragility that would make intradermal injection difficult.

Patients with end-stage renal disease (ESRD) often have impaired cellular immunity due to the effects of uremia (toxins in the blood). While the test is safe to perform, the results may be diminished. No dose adjustment is needed, but the clinical interpretation must account for the renal status.

There are no specific considerations for patients with liver disease. The diagnostic performance and safety of the extract are not affected by hepatic function.

> Important: Special populations require individualized medical assessment. Always inform your provider if you are pregnant or planning to become pregnant before any diagnostic procedure.

Listeria Monocytogenes extract functions as a diagnostic antigen for the induction of a Type IV hypersensitivity reaction. The mechanism is purely immunological and does not involve direct binding to pharmacological receptors like G-protein coupled receptors or ion channels.

Upon intradermal injection, the bacterial antigens (proteins and cell wall components) are captured by local dendritic cells. These cells migrate to the paracortical areas of regional lymph nodes, where they present the antigen to naive and memory T-cells. In individuals previously exposed to Listeria, memory Th1 cells recognize the antigen and proliferate. These activated T-cells سپس (then) migrate back to the site of injection, where they release IFN-gamma and other cytokines. This process recruits monocytes from the bloodstream, which transform into macrophages and cause the characteristic induration of a positive DTH test.

The "dose-response" in DTH testing is not linear in the traditional sense. Once a threshold amount of antigen is provided (typically 0.1 mL of a standard dilution), the size of the reaction is determined by the patient's immune vigor rather than the amount of drug. The onset of the reaction is "delayed," typically appearing after 12-24 hours, peaking at 48-72 hours, and slowly subsiding over several days. There is no development of "tolerance" in the pharmacological sense, but repeated testing at the same site can lead to a "booster effect," where the second test produces a larger reaction than the first.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Intradermal) |

| Protein Binding | N/A (Biological Extract) |

| Half-life | N/A (Local degradation) |

| Tmax | 48-72 hours (for effect) |

| Metabolism | Local Proteolysis |

| Excretion | Lymphatic Clearance |

Listeria Monocytogenes extract is a complex mixture of biological molecules. It is not a single chemical entity with a specific molecular weight or formula. It is prepared by growing Listeria monocytogenes in a suitable liquid medium, followed by filtration, purification, and standardization based on protein nitrogen content or weight/volume. The final product is a clear to slightly turbid liquid, usually preserved with 0.4% to 0.5% phenol to maintain sterility.

Listeria Monocytogenes extract is classified as a Non-Standardized Allergenic Extract. It is grouped with other diagnostic antigens like Candida albicans extract, Trichophyton extract, and Mumps Skin Test Antigen. These are distinct from standardized extracts (like Grass Pollen or Dust Mite), which have federally mandated potency units.